BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Servier readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Servier's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05987332-10793@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Darovasertib: Phase 2/3 readout est. (NCT05987332)
DESCRIPTION:Darovasertib\, phase 2/3\, Uveal Melanoma.\nStudy: IDE196 (Daro
 vasertib) in Combination With Crizotinib as First-line Therapy in Metastat
 ic Uveal Melanoma\nEstimated primary completion: 15 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/darovasertib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05987332
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03947385-10793@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Darovasertib: Phase 1/2 readout est. (NCT03947385)
DESCRIPTION:Darovasertib\, phase 1/2\, Uveal Melanoma.\nStudy: Study of IDE
 196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusi
 ons\nEstimated primary completion: 29 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/darovasertib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03947385
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907954-10793@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Darovasertib: Phase 2 readout est. (NCT05907954)
DESCRIPTION:Darovasertib\, phase 2\, Uveal Melanoma.\nStudy: (Neo)Adjuvant 
 IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma\nEstimate
 d primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/darovasertib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05907954
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501625-2899@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Tibsovo (Ivosidenib): Phase 1/2 readout est. (NCT06501625)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 1/2.\nStudy: Ivosidenib Plus Durva
 lumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With
  Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation\n
 Estimated primary completion: 13 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06501625
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907057-2899@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05907057)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidi
 ne in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AM
 L) Ineligible for Intensive Induction Chemotherapy.\nEstimated primary com
 pletion: 15 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivosidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05907057
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719348-2719@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:S241656: Phase 1/2 readout est. (NCT07719348)
DESCRIPTION:S241656\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study t
 o Evaluate S241656 Alone or in Combination in Participants With Selected M
 yeloid Malignancies\nEstimated primary completion: 1 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/s241656#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07719348
URL:https://assetmemo.bio/drug/s241656#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465953-2899@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT06465953)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Ivosidenib (IVO) Monoth
 erapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating A
 gent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation\nEs
 timated primary completion: 1 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06465953
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05876754-2899@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT05876754)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: An Early Access Study o
 f Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic 
 Cholangiocarcinoma\nEstimated primary completion: 1 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ivosidenib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05876754
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06127407-2899@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Tibsovo (Ivosidenib): Phase 3 readout est. (NCT06127407)
DESCRIPTION:Tibsovo (Ivosidenib)\, phase 3.\nStudy: Ivosidenib in Participa
 nts With Locally Advanced or Metastatic Conventional Chondrosarcoma Untrea
 ted or Previously Treated With 1 or 2 Systemic Treatment Regimens\nEstimat
 ed primary completion: 1 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivosidenib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06127407
URL:https://assetmemo.bio/drug/ivosidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227857-8920@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:S230815: Phase 1/2 readout est. (NCT07227857)
DESCRIPTION:S230815\, phase 1/2\, Epilepsy.\nStudy: A First-in-human Study 
 of S230815 in Pediatric Participants With KCNT1-related Developmental and 
 Epileptic Encephalopathy\nEstimated primary completion: 15 April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/s230815#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227857
URL:https://assetmemo.bio/drug/s230815#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-2719@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:S241656: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:S241656\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Phase
  1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
 \nEstimated primary completion: June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/s241656#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/s241656#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015190-10793@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Darovasertib: Phase 3 readout est. (NCT07015190)
DESCRIPTION:Darovasertib\, phase 3\, Uveal Melanoma.\nStudy: Neoadjuvant Da
 rovasertib in Primary Uveal Melanoma\nEstimated primary completion: Octobe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/darovasertib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701
 5190
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804186-10793@assetmemo.bio
DTSTAMP:20261121T004519Z
DTSTART;VALUE=DATE:20340331
DTEND;VALUE=DATE:20340401
SUMMARY:Darovasertib: Phase 3 readout est. (NCT07804186)
DESCRIPTION:Darovasertib\, phase 3\, Uveal Melanoma.\nStudy: Study of Adjuv
 ant Darovasertib and Crizotinib in Participants With Primary Non-metastati
 c Uveal Melanoma\nEstimated primary completion: March 2034. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/darovasertib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07804186
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
